<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931784</url>
  </required_header>
  <id_info>
    <org_study_id>INHAUH 2018-03-009</org_study_id>
    <nct_id>NCT04931784</nct_id>
  </id_info>
  <brief_title>Effect of Ultimaster Stents Treated to the Most Dilated Coronary Vessels</brief_title>
  <official_title>Prospective, Open, Randomized Study Comparing the Effects of Ultimaster® Stents Treated With Conventional Methods on Coronary Artery Lesions Compared to the Most Dilated Coronary Vessels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Inha University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with vasospasm or with negative remodeling, various vasodilator drugs used during&#xD;
      coronary angiography can dilate the diameter of the reference vessel to measure the exact&#xD;
      vessel size. In particular, nitrates are well known to induce pharmacological vasodilatory&#xD;
      effects through vascular smooth muscle relaxation In actual clinical practice, it has been&#xD;
      reported that when oral or spray-type nitrate preparations are administered to coronary&#xD;
      artery stenosis lesions, the diameter of the reference vessel expands by about 10% compared&#xD;
      to the existing vessel diameter. This may enable larger stenting in coronary artery stenosis&#xD;
      lesions. Although many patients with vascular stenosis are accompanied by vasospasm and voice&#xD;
      remodeling, in actual clinical practice, administration of vasodilators is only used in a&#xD;
      small number of patients at the discretion of the surgeon. Nitrate vasodilators administered&#xD;
      during coronary angiography are low-dose and short-acting drugs, and although a small number&#xD;
      of patients may experience side effects such as short-term lowering of blood pressure, no&#xD;
      serious side effects are reported .&#xD;
&#xD;
      On this background, this study is to evaluate whether there is a difference in the diameter&#xD;
      of the Ultimaster® stent treated with the conventional method compared to the maximally&#xD;
      dilated coronary artery, and to evaluate the stability and effectiveness after the procedure.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean stent diameter</measure>
    <time_frame>Immediately after percutaneous coronary intervention</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Failure rate of target lesion for 1-year (combination of cardiac death, target vascular myocardial infarction, target vascular revascularization)</measure>
    <time_frame>1 year after percutaneous coronary intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Vasodilation</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Nitrate Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>with administration of intra-coronary nitrate before percutaneous coronary intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>without administration of intra-coronary nitrate before percutaneous coronary intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrate</intervention_name>
    <description>Administration of intra-coronary nitrate before percutaneous coronary intervention</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Nitrate Group</arm_group_label>
    <other_name>No intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Over 19 years old&#xD;
&#xD;
          -  evidence of coronary artery disease including asymptomatic ischemia stable angina&#xD;
             acute coronary syndrome (unstable angina, non-ST segment elevation&#xD;
&#xD;
               -  myocardial infarction, ST segment elevation myocardial infarction).&#xD;
&#xD;
          -  coronary artery diameter 2.25~3.5mm, stenosis 50% or more&#xD;
&#xD;
          -  Those who voluntarily agreed in writing to participate in this clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  instability or psychogenic shock within 24 hours before percutaneous coronary&#xD;
             intervention&#xD;
&#xD;
          -  life expectancy no longer than 1 year&#xD;
&#xD;
          -  hypersensitivity or contraindications to the following drugs or substances: heparin,&#xD;
             aspirin, clopidogrel&#xD;
&#xD;
          -  patients whom researchers think unsuitable for participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sang-Don Park, Ph.D</last_name>
    <phone>821033356991</phone>
    <email>denki1@inha.ac.kr</email>
  </overall_contact>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>June 11, 2021</last_update_submitted>
  <last_update_submitted_qc>June 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Inha University Hospital</investigator_affiliation>
    <investigator_full_name>Sang-Don Park</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

